In a recent pre-print study posted to the medRxiv* server, researchers conducted a comprehensive genome-wide association study (GWAS) to elucidate the genetic architecture of circulating retinol, identify its potential causal relationships with various clinical phenotypes, and evaluate its therapeutic or nutritional implications.
Study: Genetic influences on circulating retinol and its relationship to human health. Image Credit: SciePro/Shutterstock.com.
*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Genome-wide association analyses of magnetic resonance imaging data describe the genetic architecture of 13 cortical phenotypes at both global and regional levels, implicating neurodevelopmental and constrained genes.
A new method allows large quantities of muscle stem cells to be safely obtained in cell culture. This provides a potential for treating patients with muscle diseases – and for those who would like to eat meat, but don’t want to kill animals.
Elon Musk delves into the groundbreaking potential of Neuralink, a revolutionary venture aimed at interfacing with the human brain to tackle an array of brain-related disorders. Musk envisions a future where Neuralink’s advancements lead to the resolution of conditions like autism, schizophrenia, memory loss, and even spinal cord injuries.
Elon Musk discusses the transformative power of Neuralink, highlighting its role in restoring motor control after spinal cord injuries, revitalizing brain function post-stroke, and combating genetically or trauma-induced brain diseases. Musk’s compelling insights reveal how interfacing with neurons at an intricate level can pave the way for repairing and enhancing brain circuits using cutting-edge technology.
Discover the three-layer framework Musk envisions: the primary layer akin to the limbic system, the more intelligent cortex as the secondary layer, and the potential tertiary layer where digital superintelligence might exist. Musk’s thought-provoking perspective raises optimism about the coexistence of a digital superintelligence with the human brain, fostering a harmonious relationship between these layers of consciousness.
Elon Musk emphasises the urgency of Neuralink’s mission, stressing the importance of developing a human brain interface before the advent of digital superintelligence and the elusive singularity. By doing so, he believes we can mitigate existential risks and ensure a stable future for humanity and consciousness as we navigate the uncharted territories of technological evolution.
A research team co-led by City University of Hong Kong (CityU) and The University of Hong Kong (HKU) has recently made a significant advancement in spinal cord injury treatment by using genetically-modified human neural stem cells (hNSCs).
They found that specifically modulating a gene expression to a certain level in hNSCs can effectively promote the reconstruction of damaged neural circuits and restore locomotor functions, offering great potential for new therapeutic opportunities for patients with spinal cord injury. The findings were published in the journal Advanced Science under the title “Transplanting Human Neural Stem Cells with ≈50% Reduction of SOX9 Gene Dosage Promotes Tissue Repair and Functional Recovery from Severe Spinal Cord Injury.”
Traumatic spinal cord injury is a devastating condition that commonly results from accidents such as falls, car crashes or sport-related injuries.
Remember when eggs were so high? A vaccine for birds, now that can make money. 🤔
In the past two years, a viral disease has swept across much of the planet — not Covid but a type of avian flu. It’s devastated the poultry industry in the US, Europe, and elsewhere, sickening millions of farmed birds, which either die from infection or are killed by farmers seeking to stem the spread.
The ongoing outbreak of avian flu has killed hundreds of thousands — if not millions — of wild birds, including endangered species like the California condor. It’s one of the worst wildlife disease outbreaks in history. Having now spread across five continents and hundreds of wildlife species, scientists call the current outbreak a panzootic, meaning a pandemic among animals.
“What we’re seeing right now is uncharted territory,” said Andrew Ramey, a wildlife geneticist at the US Geological Survey, one of the federal agencies involved in testing wild birds for the virus.
The number of dead birds in itself is historic, but so is the virus’s biology. Typically, avian influenza viruses only cause severe disease and death in domestic birds like chickens and farmed ducks; they sweep through populations, killing upward of 90 percent of the flock.
Scientists at Stanford University have found a way to induce cell death in cancer cells with a method that could be effective in around 50% of cancers. In a paper, “Rewiring cancer drivers to activate apoptosis,” published in Nature, the team describes a new class of molecules called transcriptional/epigenetic CIPs (TCIPs) that can activate apoptosis with the help of cancer growth gene expressions within the cancer cells.
The researchers designed small molecules that bind specific transcriptional suppressors to transcription activators. The most potent molecule created, TCIP1, works by linking small molecules that bind BCL6 to those that bind transcriptional activators BRD4.
One of the components that makes cancer cells cancerous is that they ignore signals from surrounding healthy tissues to stop growing and to initiate apoptosis or cell death. The apoptosis pathways still exist but are actively blocked in certain types of cancer where the transcription factor B cell lymphoma 6 (BCL6) binds to the promoters of apoptosis genes and suppresses their expression through epigenetic mechanisms.
The origin and early evolution of life is generally studied under two different paradigms: bottom up and top down. Prebiotic chemistry and early Earth geochemistry allow researchers to explore possible origin of life scenarios. But for these “bottom–up” approaches, even successful experiments only amount to a proof of principle. On the other hand, “top–down” research on early evolutionary history is able to provide a historical account about ancient organisms, but is unable to investigate stages that occurred during and just after the origin of life. Here, we consider ancient electron transport chains (ETCs) as a potential bridge between early evolutionary history and a protocellular stage that preceded it. Current phylogenetic evidence suggests that ancestors of several extant ETC components were present at least as late as the last universal common ancestor of life. In addition, recent experiments have shown that some aspects of modern ETCs can be replicated by minerals, protocells, or organic cofactors in the absence of biological proteins. Here, we discuss the diversity of ETCs and other forms of chemiosmotic energy conservation, describe current work on the early evolution of membrane bioenergetics, and advocate for several lines of research to enhance this understanding by pairing top–down and bottom–up approaches.
In this “Ask Me Anything” (AMA) episode, Peter delves into the realm of genetics, unraveling its connection to disease and emphasizing the value of understanding one’s genetic risks. He elucidates essential background knowledge on genetics before delving into the myriad reasons why individuals might consider genetic testing. Peter differentiates scenarios where genetic testing provides genuine insights from those where it may not be as useful. From there, Peter explores a comprehensive comparison of commercial direct-to-consumer genetic tests, providing insights on interpreting results and identifying the standout options for gaining insights into personal health.
In this sneak peek, we discuss: 00:00 — Intro. 02:09 — Defining the term “genetics” and why it’s important. 04:03 — What is DNA, and how does it impact our biology and traits? 07:13 — How are genetics passed down from parent to child? 11:44 — How much do genes vary across individuals? 16:22 — Which traits are determined by genetics versus experience or environmental factors? 22:30 — Reasons for genetic testing.
In the full episode, we also discuss: –What exactly is being measured by a genetic test?; –Testing for monogenic disorders; –Understanding polygenic risk; –Is genetic testing more important for someone who doesn’t know their family history?; –What does it mean to be positive for a particular variant?; –What does it mean to be negative for a particular variant?; –How does someone get genetic testing through their healthcare provider, and how are these tests performed?; –The financial cost of various genetic tests; –Could having a risk allele for a disease result in an increase in one’s insurance premium?; –Other risks associated with genetic testing; –How do commercial, direct-to-consumer genetic tests compare to the information one might receive from clinical genetic testing?; –Are certain direct-to-consumer tests better than others?; –How long until whole genome sequencing becomes genuinely useful?; –How useful are personalized dietary recommendations based on genetics?; –Final thoughts and advice regarding genetic testing; and. –More.
——- About:
The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 70 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.
